Industry

Study also met secondary endpoint of overall survival (OS) for patients whose tumors express PD-L1 KEYTRUDA® (pembrolizumab) plus chemotherapy (paclitaxel) with or without bevacizumab is the first immune checkpoint inhibitor-based regimen to show a statistically significant improvement in OS for ovarian cancer RAHWAY, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK), known as MSD outside of the United … [Read more…]

BALLERUP, Denmark–(BUSINESS WIRE)–In Q1, LEO Pharma continued its robust growth, driven by dermatology, and made significant strategic progress. This included expanding the launch of Anzupgo® to five markets, advancing innovation through the newly formed strategic partnership with Gilead for the STAT6 program, and significantly improving profitability with a return to a positive net profit. Q1 … [Read more…]

Results at a glance: 71.4% of MetaXplore™ reports from 4,616 patients identified actionable results 41.9% tested positive for abnormal microbiome markers linked to gastrointestinal health 9.9% tested positive for gastrointestinal markers, including inflammation, pancreatic insufficiency, or blood in stool 19.6% of reports tested positive for multiple markers (microbiome and gastrointestinal) 65% of patients reported health … [Read more…]

Study is the first demonstration of senescent neurons driving neuropathic pain1 Rubedo’s proprietary, AI-driven drug discovery platform ALEMBIC™ identified senescent neurons as novel therapeutic targets2 SAN FRANCISCO–(BUSINESS WIRE)–Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced that using open source … [Read more…]

WELIREG becomes the only approved and available treatment in the U.S. for eligible patients with advanced PPGL RAHWAY, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved WELIREG® (belzutifan), Merck’s oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, for the … [Read more…]

HOUSTON–(BUSINESS WIRE)–IPS HEART has been awarded Orphan Drug Designation (ODD) in the EU by the EUROPEAN MEDICINES AGENCY for GIVI-MPCs unique ability to create new muscle with 100% full length dystrophin in Becker Muscular Dystrophy (BMD). IPS HEART has now shown GIVI-MPCs can create new human muscle with full length human dystrophin in BMD dystrophic … [Read more…]

SAN DIEGO–(BUSINESS WIRE)–San Diego Fertility Center (SDFC), named the #1 fertility clinic in California by Newsweek in 2024, is helping families take the next step toward parenthood with a limited-time summer promotion. Patients who begin in vitro fertilization (IVF) cycles in July or August will receive $2,000 off their IVF cycle, plus additional savings on … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Leqembi Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts” report has been added to ResearchAndMarkets.com’s offering. This Leqembi market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical … [Read more…]

VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of Zenlens CHROMA HOA scleral contact lenses. Designed to correct advanced higher-order aberrations (HOA), this custom, wavefront-guided scleral lens technology delivers enhanced vision and improves clarity by … [Read more…]

Dr. Clackson is former CEO of IDRx, acquired by GSK in 2025 for up to $1.15 billion Kesmalea’s SELFTAC® platform is designed to solve the ‘size problem’ of large, bifunctional protein degraders by transforming them into small molecules SELFTAC® drug candidates are oral and CNS penetrant, combining powerful protein degradation with a rational small molecule … [Read more…]